Navigation Links
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
Date:9/24/2008

f clinical data at the European Society of Cardiologists by GlaxoSmithKline on the effect of their selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor, darapladib, on a secondary biological outcome while having no effect on inflammation or LDL-C, provides encouraging validation of the anatomical importance of reducing PLA2 activity in a cardiovascular population," said Dr. Robert S. Rosenson, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research at the University of Michigan. "The on-going FRANCIS trial with varespladib, which is designed to evaluate and repeat the results of previous clinical data from PLASMA and PLASMA2 in an ACS population, should provide additional data on an already validated predictor of cardiovascular risk (LDL-C) coupled with reductions in PLA2."

In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, clinically meaningful and statistically significant reductions in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.

Presently, the company is conducting the five hundred patient FRANCIS trial (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) to assess the impact of oral varespladib on known biological markers of cardiovascular risk in ACS patients with elevated LDL and CRP. FRANCIS will also provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the six-month trial.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and he
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
7. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
8. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
10. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
(Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
(Date:7/28/2014)... , July 28, 2014   Cardioxyl Pharmaceuticals, ... clinical trial demonstrating that CXL-1427, a novel potential treatment ... in healthy volunteers. The company has now initiated dosing ... Phase IIa clinical trial designed to further evaluate the ... levels. The Phase I clinical trial evaluated ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... , CHICAGO , July 30 ... equity firm focused exclusively on health care, announced today ... (MSD).  Headquartered in Stoughton, Massachusetts , MSD ... biomedical services and technology solutions to the growing home ...
... , CATANIA, Italy , July 30 ... European research project today announced details of the ... three-year ENIAC (European Nanoelectronics Initiative Advisory Council) project ... 3D-imaging platforms by focusing on the diagnosis and ...
Cached Medicine Technology:Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 2Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 3Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 4European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases 2European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases 3
(Date:7/28/2014)... brain was able to arouse animals receiving general anesthesia ... issue of Anesthesiology , investigators from Massachusetts General ... of either agent would move, raise their heads and ... to the ventral tegmental area (VTA). Stimulation of ... not induce the animals to wake up. , ...
(Date:7/28/2014)... The report, “Blowing Agents Market by Type, ... Forecasts to 2019” defines and segments the global ... the global consumption volume and value. , Browse ... figures spread through 226 Pages and in-depth TOC ... Blowing agents are highly utilized materials as a ...
(Date:7/28/2014)... test developed at University of Colorado Skaggs School of ... (July 28, 2014) An influential new test, discovered ... the CU School of Pharmacy, helps monitor the effectiveness ... of tenofovir/emtricitabine), which is taken once daily to prevent ... AIDS 2014 Conference and published in Lancet Infectious ...
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
Breaking Medicine News(10 mins):Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Researchers identify potential biomarker for AD 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2
... Westchester, Ill. A study in the Oct. 1 issue of ... are associated with depression, suicide ideation and attempts, and the ... , Findings suggest that the presence of insomnia in ... also may increase the severity of these problems. Results indicate ...
... reliably predict whether they will adhere to physical ... in a new study. The findings could help ... preoperative preparation to ensure they attend therapy sessions ... that can greatly affect their long-term recovery. , ...
... save more than 1 million children, Stores raise funds ... 30 Quarters found in the,bottom of purses, pockets, and ... dying for needy children. The Vitamin Shoppe is asking,everyone to ... life of a,child., Affecting up to 140 million children ...
... Emergency Service,Center (DESC) is pleased to release its ... to store and manage information about clients,services and ... both proven and a work-in-progress, and has,been under ... CHASERS has been in continuous use, and now ...
... 31, New Episodes from MARTHA SPEAKS, SUPER WHY, WORDWORLD,and CYBERCHASE ... Think, To Prepare for the Long Holiday Season Ahead, ... Treats in Moderation, ARLINGTON, Va., Sept. 30 PBS ... exploring fears on Halloween,day and preparing for the holiday season ...
... of Oklahoma Health Sciences Center has created the first genetic research ... causes blindness. The research appears in a recent issue of the ... The team ... researchers from Harvard Medical School. The group is studying how diabetes ...
Cached Medicine News:Health News:Adolescent insomnia linked to depression and substance abuse during adolescence and young adulthood 2Health News:Will patients stick to physical therapy? Questionnaire can help doctors predict 2Health News:Will patients stick to physical therapy? Questionnaire can help doctors predict 3Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3Health News:Downtown Emergency Service Center Releases CHASERS, Free Software for Homeless Service Management and Beyond 2Health News:Downtown Emergency Service Center Releases CHASERS, Free Software for Homeless Service Management and Beyond 3Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 2Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 3Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 4Health News:PBS KIDS(R) and PBS KIDS GO!(sm) Explore Halloween's Tricks and Treats 5Health News:Researchers create first model for retina receptors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: